

# Alexis Ogdie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4616516/publications.pdf>

Version: 2024-02-01

217  
papers

10,350  
citations

61984

43  
h-index

39675

94  
g-index

232  
all docs

232  
docs citations

232  
times ranked

8642  
citing authors

#	ARTICLE	IF	CITATIONS
1	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	5.6	726
2	Psoriasis and comorbid diseases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 377-390.	1.2	706
3	2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1789-1798.	0.9	545
4	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
5	Psoriasis Severity and the Prevalence of Major Medical Comorbidity. <i>JAMA Dermatology</i> , 2013, 149, 1173.	4.1	402
6	2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2557-2568.	5.6	393
7	Distinctions Between Diagnostic and Classification Criteria?. <i>Arthritis Care and Research</i> , 2015, 67, 891-897.	3.4	386
8	Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 326-332.	0.9	373
9	The Epidemiology of Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 545-568.	1.9	354
10	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	5.6	312
11	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	3.4	264
12	Obesity and the risk of psoriatic arthritis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1273-1277.	0.9	239
13	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. <i>Nature Reviews Rheumatology</i> , 2019, 15, 153-166.	8.0	208
14	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.9	194
15	Psoriasis and comorbid diseases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 393-403.	1.2	152
16	Recognizing and managing comorbidities in psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 118-126.	4.3	146
17	Imaging modalities for the classification of gout: systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1868-1874.	0.9	145
18	Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , 2020, 2, 335-343.	2.1	131

#	ARTICLE	IF	CITATIONS
19	Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. <i>Rheumatology</i> , 2014, 53, 346-352.	1.9	129
20	Prevalence and treatment patterns of psoriatic arthritis in the UK. <i>Rheumatology</i> , 2013, 52, 568-575.	1.9	118
21	Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. <i>European Heart Journal</i> , 2018, 39, 3608-3614.	2.2	115
22	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	30.5	113
23	Treatment guidelines in psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, i37-i46.	1.9	111
24	Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2017, 69, 51-57.	3.4	98
25	Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 149-153.	0.9	96
26	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.0	93
27	Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. <i>Arthritis and Rheumatology</i> , 2017, 69, 429-438.	5.6	93
28	COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. <i>Arthritis and Rheumatology</i> , 2020, 72, 1981-1989.	5.6	92
29	Seen Through Their Eyes. <i>Academic Medicine</i> , 2012, 87, 1361-1367.	1.6	77
30	Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 521-525.	0.9	77
31	Teaching about how doctors think: a longitudinal curriculum in cognitive bias and diagnostic error for residents. <i>BMJ Quality and Safety</i> , 2013, 22, 1044-1050.	3.7	75
32	Risk of Incident Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population-Based Study. <i>Journal of Investigative Dermatology</i> , 2018, 138, 760-767.	0.7	75
33	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	5.6	72
34	Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 119-123.	0.9	67
35	Comprehensive Treatment of Psoriatic Arthritis: Managing Comorbidities and Extraarticular Manifestations. <i>Journal of Rheumatology</i> , 2014, 41, 2315-2322.	2.0	66
36	The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 882-885.	0.9	62

#	ARTICLE	IF	CITATIONS
37	Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 907-911.	1.9	59
38	Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1726-1735.	0.7	57
39	Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence. <i>Current Rheumatology Reports</i> , 2015, 17, 64.	4.7	55
40	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	3.4	50
41	Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 918-922.	1.9	48
42	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016, 68, 667-672.	3.4	48
43	Patient-Reported Outcomes in Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 265-283.	1.9	46
44	Comparison of Men and Women With Axial Spondyloarthritis in the US-based Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2021, 48, 1528-1536.	2.0	44
45	The epidemiology of psoriatic arthritis: A literature review. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101692.	3.3	44
46	Subintimal Ki-67 as a synovial tissue biomarker for inflammatory arthropathies. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 162-167.	0.9	43
47	Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. <i>JAMA Dermatology</i> , 2019, 155, 700.	4.1	43
48	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	2.0	43
49	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	2.0	42
50	Locating Nucleobase Lesions within DNA Sequences by MALDI-TOF Mass Spectral Analysis of Exonuclease Ladders. <i>Chemical Research in Toxicology</i> , 2001, 14, 1058-1070.	3.3	39
51	Obesity and Psoriatic Arthritis: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 447-456.	2.3	38
52	Psoriasis and Cardiovascular Risk: Strength in Numbers Part 3. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2148-2150.	0.7	36
53	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	2.0	36
54	Comparison of expectations of physicians and patients with rheumatoid arthritis for rheumatology clinic visits: a pilot, multicenter, international study. <i>International Journal of Rheumatic Diseases</i> , 2012, 15, 380-389.	1.9	35

#	ARTICLE	IF	CITATIONS
55	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. <i>RMD Open</i> , 2016, 2, e000217.	3.8	35
56	Enhanced Patient Involvement and the Need to Revise the Core Set – Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2198-2203.	2.0	34
57	Tumor necrosis factor inhibitors in psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 899-910.	3.1	34
58	Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1636-1643.	1.2	34
59	Amyloid arthropathy associated with multiple myeloma: A systematic analysis of 101 reported cases. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 405-412.	3.4	33
60	Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-dermatology Clinics. <i>Journal of Rheumatology</i> , 2017, 44, 693-694.	2.0	33
61	Real-World Patient Experience on the Path to Diagnosis of Ankylosing Spondylitis. <i>Rheumatology and Therapy</i> , 2019, 6, 255-267.	2.3	32
62	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , 2019, 46, 475-482.	2.0	31
63	Psoriatic arthritis and the association with cardiometabolic disease: a narrative review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2199827.	2.7	31
64	The Changing Face of Clinical Trials in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2017, 19, 21.	4.7	29
65	Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis. <i>JAMA Network Open</i> , 2021, 4, e2119400.	5.9	29
66	Does biologic therapy impact the development of PsA among patients with psoriasis?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 80-86.	0.9	29
67	Diagnostic Delay in Psoriatic Arthritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2021, 48, 1410-1416.	2.0	25
68	The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population-Based Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1878-1885.	5.6	25
69	Identification of Risk Factors for Psoriatic Arthritis. <i>Archives of Dermatology</i> , 2010, 146, 785-8.	1.4	24
70	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969.	2.0	24
71	Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001486.	3.8	24
72	Patient perspectives on the pathway to psoriatic arthritis diagnosis: results from a web-based survey of patients in the United States. <i>BMC Rheumatology</i> , 2020, 4, 2.	1.6	23

#	ARTICLE	IF	CITATIONS
73	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. <i>Nature Reviews Rheumatology</i> , 2021, 17, 238-243.	8.0	23
74	Evolving role of FDG PET imaging in assessing joint disorders: a systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1939-1955.	6.4	22
75	The preclinical phase of PsA: a challenge for the epidemiologist. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1481-1483.	0.9	22
76	Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics. <i>Current Rheumatology Reports</i> , 2018, 20, 76.	4.7	22
77	Pediatric Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2018, 3, 131-136.	0.7	22
78	Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>ACR Open Rheumatology</i> , 2020, 2, 449-456.	2.1	22
79	Reliability and Validity of Cutaneous Sarcoidosis Outcome Instruments Among Dermatologists, Pulmonologists, and Rheumatologists. <i>JAMA Dermatology</i> , 2015, 151, 1317.	4.1	21
80	Discordance of the Framingham cardiovascular risk score and the 2013 American College of Cardiology/American Heart Association risk score in systemic lupus erythematosus and rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 467-474.	2.2	21
81	Patient's experience of psoriatic arthritis: a conceptual model based on qualitative interviews. <i>RMD Open</i> , 2020, 6, e001321.	3.8	21
82	A roadmap for education to improve the quality of care in gout. <i>Current Opinion in Rheumatology</i> , 2010, 22, 173-180.	4.3	20
83	Classification and Outcome Measures for Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 246.	2.6	20
84	Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. <i>Rheumatology</i> , 2022, 61, 1877-1884.	1.9	20
85	Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis: A Set of Parallel Case-control Studies. <i>Journal of Rheumatology</i> , 2022, 49, 53-59.	2.0	19
86	Increased angiogenesis and cellular proliferation as hallmarks of the synovium in chronic septic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 1137-1146.	6.7	18
87	Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 237.	1.9	18
88	Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). <i>Rheumatology</i> , 2020, 59, 1495-1504.	1.9	18
89	Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>RMD Open</i> , 2020, 6, e001042.	3.8	18
90	Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 566-572.	0.9	18

#	ARTICLE	IF	CITATIONS
91	3'-Exonuclease resistance of DNA oligodeoxynucleotides containing O6-[4-oxo-4-(3-pyridyl)butyl]guanine. <i>Nucleic Acids Research</i> , 2003, 31, 1984-1994.	14.5	17
92	Barriers to and Facilitators of a Career as a Physician-Scientist Among Rheumatologists in the US. <i>Arthritis Care and Research</i> , 2015, 67, 1191-1201.	3.4	17
93	Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2020, 47, 826-834.	2.0	17
94	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e23-e23.	0.9	16
95	Identification of broadly discriminatory tissue biomarkers of synovitis with binary and multicategory receiver operating characteristic analysis. <i>Biomarkers</i> , 2010, 15, 183-190.	1.9	15
96	Effect of Multidomain Disease Presentations on Patients With Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2021, 48, 698-706.	2.0	15
97	Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. <i>JAMA Dermatology</i> , 2022, 158, 252.	4.1	15
98	Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1674-1680.	2.4	14
99	Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 638-647.	2.0	14
100	Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. <i>Journal of Rheumatology</i> , 2020, 47, 1496-1505.	2.0	14
101	Changing health behaviours in rheumatology: an introduction to behavioural economics. <i>Nature Reviews Rheumatology</i> , 2020, 16, 53-60.	8.0	14
102	Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2021, 48, 520-526.	2.0	14
103	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	2.0	14
104	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 1137-1147.	1.9	13
105	Prevalence and risk factors for patient-reported joint pain among patients with HIV/Hepatitis C coinfection, Hepatitis C mono-infection, and HIV mono-infection. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 93.	1.9	12
106	Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Inter-Institutional Adult Rheumatology Mentoring Program. <i>Arthritis Care and Research</i> , 2018, 70, 445-453.	3.4	12
107	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 31-58.	0.7	12
108	Risk of Malignancy in Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 463-511.	1.9	12



#	ARTICLE	IF	CITATIONS
109	Reliability and Validity of Patient-reported Outcomes Measurement Information System Short Forms in Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2020, 47, 1182-1188.	2.0	12
110	Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. <i>Journal of Rheumatology</i> , 2022, 49, 885-893.	2.0	12
111	Amyloid arthropathy associated with multiple myeloma: polyarthritis without synovial infiltration of CD20+ or CD38+ cells. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 28-34.	3.0	11
112	Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 451-459.	0.3	11
113	Measuring Outcomes in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 82-109.	3.4	11
114	Measuring Outcomes in Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2020, 72, 47-71.	3.4	11
115	Disease Characteristics, Quality of Life, and Work Productivity by Enthesitis Site: Real-world Data From the US Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2021, 48, 367-375.	2.0	11
116	Racial Differences in Prevalence and Treatment for Psoriatic Arthritis and Ankylosing Spondylitis by Insurance Coverage in the USA. <i>Rheumatology and Therapy</i> , 2021, 8, 1725-1739.	2.3	11
117	Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 252.	3.5	11
118	Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination. , 2021, 3, e0578.		11
119	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001845.	3.8	11
120	Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence. <i>Rheumatology and Therapy</i> , 2022, 9, 803-821.	2.3	11
121	Epidemiology and Natural History of Psoriatic Arthritis: an UpdateWhat Dermatologists Need to Know. <i>Current Dermatology Reports</i> , 2013, 2, 66-76.	2.1	10
122	Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. <i>Archives of Dermatological Research</i> , 2018, 310, 701-710.	1.9	10
123	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. <i>Current Rheumatology Reports</i> , 2020, 22, 78.	4.7	10
124	Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. <i>Journal of Rheumatology</i> , 2021, 48, 693-697.	2.0	10
125	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	2.0	10
126	Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis. <i>BMC Rheumatology</i> , 2020, 4, 39.	1.6	9



#	ARTICLE	IF	CITATIONS
127	Physical Activity Patterns in People With Inflammatory Arthritis Indicate They Have not Received Recommendationâ€Based Guidance From Health Care Providers. <i>ACR Open Rheumatology</i> , 2020, 2, 582-587.	2.1	9
128	A comparison of physical function instruments in psoriatic arthritis: HAQ-DI <i>vs</i> MDHAQ <i>vs</i> PROMIS10 global physical health. <i>Rheumatology</i> , 2021, 60, 2307-2316.	1.9	9
129	Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1726.	7.4	9
130	Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients: A Qualitative Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1015-1030.	2.3	9
131	Evaluation of Clinical Diagnosis of Axial Psoriatic Arthritis (PsA) or Elevated Patient-reported Spine Pain in CorEvitasâ€™ PsA/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2022, 49, 281-290.	2.0	9
132	AB0826â€Imaging Modalities for the Classification of Gout: Systematic Literature Review and Meta-Analysis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1076.2-1076.	0.9	8
133	<scp>SEAM</scp>â€PsA: Seems Like Methotrexate Works in Psoriatic Arthritis?. <i>Arthritis and Rheumatology</i> , 2019, 71, 1027-1029.	5.6	8
134	Impact of Industry Payments on Prescribing Patterns for Tumor Necrosis Factor Inhibitors Among Medicare Beneficiaries. <i>Journal of General Internal Medicine</i> , 2019, 34, 176-178.	2.6	8
135	Persistent premature mortality gap in dermatomyositis and polymyositis: a United Kingdom general population-based cohort study. <i>Rheumatology</i> , 2020, 60, 2653-2660.	1.9	8
136	Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201668.	2.0	8
137	Does psoriasis treatment affect PsA development?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 708-709.	8.0	8
138	Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results from a Real-World Survey in the USA and Europe. <i>Rheumatology and Therapy</i> , 2022, 9, 285-293.	2.3	8
139	Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 703-705.	2.0	7
140	Potential risk factors for reactive arthritis and persistence of symptoms at 2Âyears: a case-control study with longitudinal follow-up. <i>Clinical Rheumatology</i> , 2018, 37, 415-422.	2.2	7
141	Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020, 2, 543-554.	2.1	7
142	Probiotic Use and Psoriatic Arthritis Disease Activity. <i>ACR Open Rheumatology</i> , 2020, 2, 330-334.	2.1	7
143	Secukinumab in United States Biologic-NaÃve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. <i>Journal of Rheumatology</i> , 2022, 49, 894-902.	2.0	7
144	Light and Electron Microscopic Features of Synovium in Patients with Psoriatic Arthritis. <i>Ultrastructural Pathology</i> , 2012, 36, 207-218.	0.9	6

#	ARTICLE	IF	CITATIONS
145	Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1048-1051.	2.0	6
146	Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 970-973.	2.0	6
147	Frequency and Predictors of Communication About High Blood Pressure in Rheumatoid Arthritis Visits. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 210-217.	0.9	6
148	Treatment Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. <i>Arthritis Care and Research</i> , 2020, 72, 814-821.	3.4	6
149	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1158-1181.	3.4	6
150	Micronutrients: Essential Treatment for Inflammatory Arthritis?. <i>Current Rheumatology Reports</i> , 2020, 22, 87.	4.7	6
151	Age-appropriate cancer screening: A cohort study of adults with psoriasis prescribed biologics, adults in the general population, and adults with hypertension. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1602-1609.	1.2	6
152	Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1574-1578.	5.6	6
153	Time to transition from psoriasis to psoriatic arthritis: A population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151949.	3.4	6
154	Synovial Biopsy Findings in Arthritis Associated with Hepatitis C Virus Infection. <i>Journal of Rheumatology</i> , 2010, 37, 1361-1363.	2.0	5
155	Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease. <i>Leukemia and Lymphoma</i> , 2013, 54, 1235-1241.	1.3	5
156	Incidence of <i>Pneumocystis jirovecii</i> and Adverse Events Associated With <i>Pneumocystis</i> Prophylaxis in Children Receiving Glucocorticoids. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 283-289.	1.3	5
157	The need for strategies to address obesity and psoriatic arthritis prevention in psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, 523-524.	1.5	5
158	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 58-66.	2.0	5
159	Real-World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study. <i>ACR Open Rheumatology</i> , 2021, , .	2.1	5
160	Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry. <i>Rheumatology and Therapy</i> , 2022, 9, 735-751.	2.3	5
161	International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 684-685.	2.0	4
162	Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 54-61.	1.2	4

#	ARTICLE	IF	CITATIONS
163	Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. <i>RMD Open</i> , 2021, 7, e001609.	3.8	4
164	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1117-1124.	3.4	4
165	AB0778â€¦ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND DISEASE ACTIVITY IN BIMEKIZUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1687.1-1687.	0.9	4
166	Psoriatic arthritis: prospects for the future. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210867.	2.7	4
167	OUP accepted manuscript. <i>Rheumatology</i> , 2022, , .	1.9	4
168	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, 49, 694-699.	2.0	4
169	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa032.	0.7	3
170	The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. <i>Clinical Rheumatology</i> , 2021, 40, 3667-3677.	2.2	3
171	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1547-1551.	2.0	3
172	GRAPPA 2017 Project Report. <i>Journal of Rheumatology</i> , 2018, 94, 48-51.	2.0	3
173	Association between depression, anxiety, chronic pain, or opioid use and tumor necrosis factor inhibitor persistence in inflammatory arthritis. <i>Clinical Rheumatology</i> , 2022, , 1.	2.2	3
174	Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2022, 49, 700-706.	2.0	3
175	Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons Living With Psoriatic Disease. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022, 7, 174-186.	0.7	3
176	FRIO463â€¦ENTHESITIS, DACTYLITIS, AND AXIAL DISEASE IN PSORIATIC ARTHRITIS (PSA): IMPACT ON PATIENT QUALITY OF LIFE AND WORK PRODUCTIVITY. , 2019, , .		2
177	Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 267-283.	3.0	2
178	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2021, , jrheum.201679.	2.0	2
179	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 367-386.	3.4	2
180	AB0560â€¦EFFECT OF DELCRAVACITINIB ON THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PsAID) QUESTIONNAIRES 12 AND 9: ANALYSIS OF A PHASE 2 STUDY OF ACTIVE PSORIATIC ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1316-1317.	0.9	2

#	ARTICLE	IF	CITATIONS
181	AB0741â€¦ACHIEVEMENT OF CDAPSA LOW DISEASE ACTIVITY OR REMISSION IS ASSOCIATED WITH CONTROL OF ARTICULAR AND EXTRA-ARTICULAR MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN SUBJECTS TREATED WITH APREMILAST. , 2019, , .		1
182	FRI0460â€¦IMPACT OF MULTIDOMAIN DISEASE PRESENTATIONS ON OVERALL DISEASE BURDEN AMONG PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY. , 2019, , .		1
183	SAT0343â€¦BURDEN OF DISEASE AT TREATMENT INITIATION AMONG BIOLOGIC-NAVE PATIENTS WITH OLIGOARTICULAR VERSUS POLYARTICULAR PSORIATIC ARTHRITIS IN THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS REGISTRY. , 2019, , .		1
184	FRI0459â€¦PREVALENCE OF DISEASE DOMAIN PRESENTATIONS AMONG PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY. , 2019, , .		1
185	POS1063â€¦RHEUMATOLOGIST AND PATIENT PERSPECTIVES ON IMPLEMENTING CARDIOVASCULAR RISK PREVENTION IN THE MANAGEMENT OF PSORIASIS: A QUALITATIVE STUDY. Annals of the Rheumatic Diseases, 2021, 80, 810.2-810.	0.9	1
186	AB0553â€¦BASELINE DISEASE ACTIVITY AS A PREDICTOR FOR ACHIEVING cDAPSA TREATMENT TARGETS WITH APREMILAST IN DMARD-NAIVE PATIENTS WITH MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 1311-1311.	0.9	1
187	Dr. Mease et al reply. Journal of Rheumatology, 2021, 48, jrheum.210750.	2.0	1
188	SAT0221â€¦Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. , 2018, , .		1
189	FRI0356â€¦BURDEN OF DISEASE IN PATIENTS INITIATING APREMILAST TREATMENT: 2014-2019 FINDINGS FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS REGISTRY. Annals of the Rheumatic Diseases, 2020, 79, 774-775.	0.9	1
190	Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 206-217.	0.9	1
191	Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2022, , jrheum.211322.	2.0	1
192	Insomnia From Disease or Disaster?. Academic Medicine, 2013, 88, 436.	1.6	0
193	SAT0317â€¦Tofacitinib in patients with psoriatic arthritis and metabolic syndrome: a post-hoc analysis of phase 3 studies. , 2018, , .		0
194	FRI0180â€¦Diagnosis journey of patients with ankylosing spondylitis in the united states. , 2018, , .		0
195	AB0768â€¦BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITIS. , 2019, , .		0
196	THU0397â€¦CLINICAL CHARACTERISTICS AND TREATMENT PROFILES OF PATIENTS WITH ANKYLOSING SPONDYLITIS WHO INITIATED SECUKINUMAB AND OTHER BIOLOGICS: RESULTS FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY. , 2019, , .		0
197	FRI0429â€¦NON TOPICAL PHARMACOLOGICAL TREATMENT OF EARLY, UNTREATED (DMARD-NAËVE, SYSTEMIC) Tj ETQq1 0 0.7843		0
198	FRI0462â€¦UNDERSTANDING MEDIATORS OF PAIN REDUCTION IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH TOFACITINIB: ROLE OF INFLAMMATION. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
199	SAT0367â€¦PSAID9 IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH FILGOTINIB VS PLACEBO: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY. , 2019, , .		0
200	AB0767â€¦MULTI-SYMPOM IMPACT ON THE EQ-5D INDEX IN BIO-NAÏVE ACTIVE PSORIATIC ARTHRITIS PATIENTS: AN ANALYSIS THROUGH WEEK 24 OF THE GO-VIBRANT STUDY. , 2019, , .		0
201	AB0892-HPRâ€¦PATIENT PERSPECTIVES ON PROVIDER PRACTICES LEADING TO AN AXIAL SPONDYLOARTHRITIS DIAGNOSIS: A QUALITATIVE STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1469.2-1470.	0.9	0
202	OPO231â€¦DIFFERENCES IN REAL-WORLD PATIENT CHARACTERISTICS OF 8921 PSORIASIS PATIENTS WITH AND WITHOUT COMORBID PSORIATIC ARTHRITIS USING THE UK BADBIR DATABASE. Annals of the Rheumatic Diseases, 2021, 80, 141-141.	0.9	0
203	POS1052â€¦PSORIATIC ARTHRITIS AND OBESITY IMPACT DRUG PERSISTENCE IN USTEKINUMAB-TREATED PATIENTS WITH PSORIASIS IN THE BRITISH ASSOCIATION OF DERMATOLOGISTS BIOLOGIC AND IMMUNOMODULATORS REGISTER (BADBIR): A 10-YEAR FOLLOW-UP STUDY. Annals of the Rheumatic Diseases, 2021, 80, 804-805.	0.9	0
204	POS1474-HPRâ€¦PERSONAL EXPERIENCES WITH DIAGNOSTIC DELAY AMONG AXIAL SPONDYLOARTHRITIS PATIENTS â€œ A QUALITATIVE STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1022.2-1022.	0.9	0
205	POS0062-PAREâ€¦REAL-WORLD PATIENT EXPERIENCE AND TREATMENT PREFERENCES IN PATIENTS WITH PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 237.2-238.	0.9	0
206	Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores. Clinical Trials, 2021, 18, 541-551.	1.6	0
207	AB0849â€¦Correlation between rapid3 and promis10 in patients with ankylosing spondylitis. , 2018, , .		0
208	AB0904â€¦Correlation of rapid3 and promis10 in patients with psoriatic arthritis. , 2018, , .		0
209	THU0292â€¦Diagnostic experiences of patients with psoriatic arthritis: misdiagnosis is common. , 2018, , .		0
210	OPO247â€¦PERSISTENT PREMATURE MORTALITY GAP IN IDIOPATHIC INFLAMMATORY MYOPATHY: A GENERAL POPULATION-BASED COHORT STUDY. Annals of the Rheumatic Diseases, 2020, 79, 155.1-156.	0.9	0
211	SAT0404â€¦INCIDENCE OF PSORIATIC ARTHRITIS FROM 2000-2017: A POPULATION-BASED STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1154.1-1154.	0.9	0
212	FRI0358â€¦USAGE OF C-REACTIVE PROTEIN TESTING IN THE DIAGNOSIS AND MONITORING OF PSORIATIC ARTHRITIS (PSA): RESULTS FROM A REAL-WORLD SURVEY IN THE US AND EUROPE. Annals of the Rheumatic Diseases, 2020, 79, 775.2-776.	0.9	0
213	AB0818â€¦SKIN INVOLVEMENT IN PSORIATIC ARTHRITIS (PsA) - THE INCREMENTAL IMPACT OF PSORIASIS ON QUALITY OF LIFE, DISABILITY AND WORK PRODUCTIVITY: REAL-WORLD SURVEY IN US AND EUROPE. Annals of the Rheumatic Diseases, 2020, 79, 1711.2-1712.	0.9	0
214	Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting. Journal of Rheumatology, 2022, , jrheum.211328.	2.0	0
215	Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. Journal of Rheumatology, 2022, , jrheum.211337.	2.0	0
216	P266â€¦Secukinumab provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of five phase 3 studies. Rheumatology, 2022, 61, .	1.9	0

#	ARTICLE	IF	CITATIONS
217	Drs. Meer and Ogdie reply. <i>Journal of Rheumatology</i> , 2022, 49, 1179-1179.	2.0	0